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Abstract: Imatinib mesylate (IM), an original Abl tyrosine kinase inhibitor, entered the   clinics in 
1998 for the treatment of patients with chronic myeloid leukemia (CML). The drug is universally 
considered the treatment of choice for most, if not all, patients with CML. Importantly, lessons 
learned from patients with CML have been applied successfully for the treatment of patients 
with other disorders where IM has since been found to be active by   virtue of its   ability to target 
other kinases, such as c-kit in patients with gastrointestinal stromal tumors. IM is   associated 
with mild to moderate toxicity, mostly reversible by dose reduction or   discontinuation of the 
drug. Most adverse effects occur within the first 2 years of starting therapy; however, late effects, 
many being unique, are now being recognized. In this report, we assess the toxicity associated 
with IM, with an emphasis on the long-term adverse effects.
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Introduction
Imatinib mesylate (IM) (Gleevec®, Novartis), a 2-phenylaminopyrimidine derivative, is 
a potent inhibitor of targeted protein tyrosine kinases, including BCR-ABL, c-kit, and 
platelet-derived growth factor receptor (PDGF-R), and was developed in the mid-1990s 
against a background of some uncertainty.1–3 The drug appears to work principally by occu-
pying the ATP binding site of the BCR-ABL oncoprotein and thereby preventing phos-
phorylation of the substrate and interrupting contact with the effector protein. This results 
in abrogating the enzymatic function of the Bcr-Abl oncoprotein (Figure 1).
IM was first used in 1998 to treat patients with chronic myeloid leukemia (CML) in 
chronic phase (CP) resistant to interferon-α, and early results showed that it was able 
to re-establish Ph-negative (presumably normal) hematopoiesis in a proportion of these 
patients.4 This led to an international prospective clinical study (IRIS) in which newly 
diagnosed patients with CML in CP were randomly allocated to receive either IM at a 
dose of 400 mg daily administered orally or a combination of interferon-α and cytarabine. 
The preliminary results were published in 2003 and updated periodically, the latest being 
in 2009.5–7 The results clearly demonstrated that nearly all patients achieved a complete 
hematologic response, with a significant proportion achieving a complete cytogenetic 
response (CCyR) and a minority achieving a complete molecular remission.
Although IM at a dose of 400 mg daily yields excellent clinical results, higher 
doses (600–800 mg daily) have been shown to yield more rapid hematologic control 
and more rapid achievement of CCyR compared with the cohort receiving 400 mg/day. 
The toxicity, however, associated with higher doses can sometimes be excessive Biologics: Targets & Therapy 2010:4
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Figure 1 Mode of action of imatinib mesylate. The phosphorylation of a substrate is shown schematically. ATP occupies the pocket in the ABL component of BCR-ABL 
oncoprotein. The substrate then detaches itself from the BCR-ABL oncoprotein and makes functional contact with a further downstream effector molecule. when imatinib 
occupies the ATP binding site, it prevents phosphorylation of the substrate. This molecule in turn fails to make contact with the effector protein and the signal transduction 
pathway that would otherwise transmit the leukemia signal is interrupted. Reproduced with permission from Goldman and Mughal.70
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resulting in frequent dose interruption and dose reduction.8,9 
It is of interest that one of the recent studies confirmed this 
more rapid response with the higher dosage but suggested 
that by 18 months the short-term superiority had been lost.10 
At present, it therefore seems reasonable to recommend that 
the best starting dose remains 400 mg/day.
IM is associated with toxicity, though most of the adverse 
effects attributed occur within the first 2 years of starting 
therapy and some reverse with continued   treatment at the 
same dose. Toxicity appears mild to moderate in most 
instances and appears easily manageable and   potentially 
reversible. Some patients may experience lethargy and 
develop different types of rashes; others gain weight 
from fluid retention, especially infraorbital edema but 
  occasionally much more generalized, which responds in 
some cases to diuretics. Other effects include bone pain, 
which can sometimes be debilitating. Liver chemistry can be 
abnormal, and this may, on rare occasions, progress to liver 
failure. Rare incidences of prolongation of the QTc   interval 
on the electrocardiograph have been reported. A small 
proportion of patients in CP who start IM at 400 mg/day 
experience cytopenias within the first year of therapy. They 
typically develop neutropenia and/or thrombocytopenia and 
sometimes anemia.
In general, all these side effects have been grade 1 or 2 and 
reversible on temporarily interrupting or stopping the drug. 
It is possible that some patients, for example older patients, 
and those with impaired cardiac function might perhaps be 
more susceptible to the adverse effects, particularly those 
which are long term. Herein, we assess the scenario with an 
emphasis on the long-term adverse effects associated with 
IM treatment for patients with CML in CP.
Cardiac toxicity
There has been much speculation pertaining to the potential 
cardiac toxicity associated with IM. One report suggested 
an increase risk of cardiac failure in patients taking IM for 
longer term, but subsequently extensive studies in   different 
specialist centers from both sides of the Atlantic failed 
to   substantiate this contention.7,11–14 This appears to be at 
  variance to some of the other tyrosine kinase inhibitors 
(TKIs), such as sunitinib and sorafenib, where the risk 
associated with cardiac toxicity, compared with the general 
population in patients who have no evidence of a pre-existing 
cardiac problems, appears higher.15
In vitro preclinical studies conducted on human 
  cardiomyocytes and murine models determined a   possible 
pathway of cardiotoxicity involving the endoplasmic Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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  reticulum stress response and the effects of c-Abl inhibition.11 
The investigators speculated that cardiac toxicity might be 
mediated by Jun N-terminal kinases leading to mitochondrial 
dysfunction and approximately a 65% decrease in available 
ATP. Park et al studied 16 patients with gastrointestinal 
stromal tumors (GIST), but not CML, and found elevated 
N-terminal pro-B-type natriuretic peptide (BNP) levels in 
2 patients who developed heart failure.16
The general consensus is that the majority of patients 
who develop cardiotoxicity, heart failure, and/or myocardial 
infarction are older (.65 years old) and have pre-existing 
cardiac risk factors or existing cardiac disease.17,18 While 
overt clinical heart failure may well be of rare incidence 
in patients taking IM, studies to access early signs of heart 
  failure have been undertaken. Measures of cardiac function 
via laboratory findings were evaluated to detect the early 
onset of cardiotoxicity. Perik et al followed N-terminal 
pro-BNP and serum cardiac troponin T for 9 months in 
55 patients with GIST on IM to determine if IM caused 
subclinical cardiotoxicity.19 Two patients developed elevated 
levels, one with existing heart failure and the other with a 
history of heart failure due to mitral valve regurgitation. Also, 
Tiribelli et al reported similar results following N-terminal 
pro-BNP levels in 49 patients with CML.20
Other cardiac adverse effects include pericarditis, tachy-
cardia, hypertension, and hypotension and collectively the 
incidence appears less than 1.0%. It seems reasonable to state 
that, based on currently available evidence, cardiac toxicity 
does not appear to be a significant risk factor of long-term IM 
therapy. It will, however, appear prudent to remain vigilant. 
Clearly, patients with a pre-existing cardiac problem should 
be observed very closely and if signs of cardiac dysfunction 
develop, alternative treatment should be considered.
Abnormal bone and mineral 
metabolism
Many efforts have been made to study the effect of IM on 
bone and mineral metabolism. A principal study was con-
ducted by Berman et al.21 They assessed patients on IM for 
either GIST or CML and noted that hypophosphatemia with 
associated bone and mineral metabolic changes developed in 
a significant number of patients. The authors hypothesized 
that abnormalities in bone and mineral metabolism may be 
secondary to hypophosphatemia, but also as a direct result 
of inhibiting the PDGF-R. There is some support for this 
notion from observations in cultured osteoprogenitor and 
osteoblasts from fetal rats, for which PDGF-R α gene was 
found to be present.22 Also replication and migration of rat 
osteoblasts secondary to PDGR-AA and PDGF-BB has been 
shown.23,24 It has also been suggested using prospectively 
collected data that altered bone remodeling and secondary 
hyperparathyroidism apparently occur in the early stages of 
IM therapy.25 It has been postulated that IM directly stimu-
lates osteoblast bone building activity and limits osteoclast 
bone resorption activity (Figure 2), resulting in a net flux 
of calcium from extracellular fluid into bone, a decreased 
serum calcium level, and a compensatory rise in the level 
of parathyroid hormone, thus leading to phosphaturia and 
hypophosphatemia.26 More recently, human bone marrow 
mesenchymal stem cells (hBM-MSCs) were evaluated to 
determine their response to imatinib.27 After 21 days of 
culture, hBM-MSCs treated with IM showed morphological 
alteration, with increased extracellular mineralization and 
mRNA expression of osteogenic markers, such as RUNX2, 
osteocalcin, and bone morphogenetic protein-2.27 These data 
suggested that IM potentially favors osteoblastogenesis.
The longer term effects of IM therapy on bone   remodeling 
have also been studied. Fitter et al evaluated the effect of 
long-term therapy on osteoblastic function in an attempt to 
evaluate the effects of IM on skeletal metabolism.28 This 
was done by performing a pre- and (2–4 year) post-treatment 
analysis on patients’ bone marrow. The authors observed 
an increase in total bone volume along with a significant 
decrease in serum phosphate and calcium concentrations after 
extended IM therapy. They speculated that IM restrains bone 
resorption (by inhibiting c-Fms on osteoclasts) and stimulates 
bone formation (by inhibiting PDGF-R on osteoblasts), thus 
sequestrating both calcium and phosphate in bone. This can 
result in secondary hyperparathyroidism, which decreases 
renal phosphate absorption, leading to hypophosphatemia.
The clinical implications of the above studies are lim-
ited at the current time. While it appears that monitoring 
phosphorous and vitamin D levels may be reasonable, 
further studies are desirable, particularly to determine the 
long-term effects. The Société Française des Cancers de 
l’enfant (SFCE) recently reported the results of an   open-label, 
multicentric phase IV trial assessing the efficacy and safety 
of IM in   children and adolescents with untreated CML 
and confirmed a significant decrease of height in 22 of the 
44 study patients.29 This negative impact of IM on skeletal 
growth also merits further study.
Pregnancy
Since IM first entered the clinics almost a decade ago, for the 
management of patients with CML, there have been a number 
of ad hoc observations and reports suggesting the potential Biologics: Targets & Therapy 2010:4
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Figure 2 Development of osteoblasts and osteoclasts from bone marrow progenitors. Factors affecting the development and function of these cells, bone resorption by 
osteoclast, and new bone formation by osteoblasts. Copyright © 2006. Reproduced with permission from valsamis et al; licensee BioMed Central Ltd.  Alsamis HA, et al. 
Antiepileptic drugs and bone metabolism. Nutr Metab. 2006;3:36. doi:10.1186/1743-7075-3-36.71
Abbreviations: GH, growth hormone; iGF, insulin-like growth factors; PTH, parathyroid hormone.
Table 1 Most frequently reported adverse effects in patients with CML in CP treated with imatinib
Most common adverse 
effects (by 5 years)
All grades of adverse 
effects in patients (%)
Grade 3/4 adverse effects   
in patients (%)
Superficial edema 60 2
Nausea 50 1
Muscle cramps 49 2
Musculoskeletal pain 47 5
Diarrhea 45 3
Rash/skin problems 40 3
Fatigue 39 2
Headache 37 ,1
Abdominal pain 37 4
Joint pain 31 3
Note: Only serious adverse effects were collected after 2005; grade 3/4 adverse effects decreased in incidence after years 1–2.
Abbreviations: CML, chronic myeloid leukemia; CP, chronic phase.
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detrimental effect of IM on the outcomes of pregnancy when 
either partner has been exposed to the drug. In preclinical data, 
mice were noted to have numerous teratogenic effects including 
perinatal mortality; abnormal spleen, head, and eye develop-
ment; and abnormal immune system function.30 This has been 
speculated to be possibly related to the loss of Abl for a proper 
embryonic development. Based on such preclinical data, the 
manufacture of IM (Novartis) issued strict recommendations 
for female patients of child-bearing age, stating avoidance of 
IM when attempting to become or becoming pregnant.
A small study from Houston in 2006 described outcomes 
of pregnancies in 19 patients undergoing treatment with IM. 
It is of interest that this study assessed 10 females and 8 males 
whose partners were pregnant.31 IM therapy was discontinued 
in all female patients immediately following the confirmation 
of pregnancy. The majority of patients conceived without 
complication, and the authors concluded that conception among 
patients with CML receiving IM can ultimately lead to normal 
pregnancies, but given the low number of patients, an effect on 
miscarriages and birth abnormalities could not be ruled out.Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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A much larger international retrospective study of 
180 female patients exposed to IM during pregnancy was 
published in 2008, with the timing of exposure available in 
146 of 180 patients.32 Exposure to IM occurred in 103 of 
146 patients during the first trimester; 38 of 146 patients 
received the drug throughout their pregnancy. Data on the 
outcome of pregnancy were available for 125 of 180 (69%) 
patients. Half of these patients (63 of 125; 35% of all pregnant 
patients) gave birth to normal live infants; 35 (28%) patients 
elected to have the pregnancy terminated, including 3 who 
were identified to have fetal abnormalities; and 18 (14.4%) 
patients had a spontaneous abortion. Of the remaining 9 of 
125 pregnancies, there were 8 live births and 1 stillbirth, all 
with congenital abnormalities. In sum, therefore, there were 
12 infants with congenital abnormalities in this series of 
patients, including 3 with a combination of similar skeletal 
abnormalities, including deformities of skull bones. The 
authors felt that the incidence of these abnormalities was in 
excess of the reported incidence in general population and 
were probably related to IM exposure.
It is, therefore, prudent to advise female patients to avoid 
conception while on IM. The management of women who 
do conceive while on IM is enigmatic, with some   specialists 
advocating a fine balance of the risks to both the mother 
and the fetus versus the potential for a loss of response on 
  discontinuing IM (Table 2). Parenthetically, it should be 
noted that since IM is secreted in breast milk, breastfeeding 
is not recommended while on IM.
Current evidence does not suggest a congenital risk in male 
patients who are on IM at time of their partner conceiving, but 
it would appear reasonable to remain cautious. Oligospermia 
and reduced sperm motility have been observed in animals 
and humans treated with IM.33 A potential option might be to 
cryopreserve sperms prior to starting therapy with IM.34
Gynecomastia
It has been shown that both c-kit and PDGF-R are expressed 
in the male testis. IM can decrease testosterone production by 
the inhibition of these receptors.35 Decreased testosterone pro-
duction over time can lead to gynecomastia, which has been 
noted with long-term IM exposure and is possibly secondary 
to inhibition of c-kit and PDGF-R. Gambacorti-  Passerini et al 
evaluated hormone levels and clinical evidence of gyneco-
mastia in 38 patients at baseline and on treatment with ima-
tinib.35 In the majority of patients studied, IM was associated 
with a decrease in the production of testicular hormones, and 
in 7 patients gynecomastia was noted. Gynecomastia has also 
been reported in a patient on IM for GIST.36
Hypothyroidism
Current evidence suggests an association between some 
TKIs, such as sunitinib and sorafenib, but not IM, and 
hypothyroidism.37–39 IM, however, can affect patients 
treated with levothyroxine for hypothyroidism. de Groot 
et al described a cohort of 11 patients (10 with medullary 
thyroid carcinoma and 1 with GIST) treated with IM and 
levothyroxine concurrently.40  Thyroid function was evaluated 
before, during, and 2 weeks after therapy with IM or after 
levothyroxine was discontinued. Symptomatic hypothyroid-
ism was noted in all patients who previously underwent 
thyroidectomy but was not present in those who did not 
undergo surgery. Patients who had undergone thyroidectomy 
had markedly elevated thyroid-stimulating hormone (TSH) 
levels and required an increase of levothyroxine during IM 
dosing. TSH decreased after discontinuing treatment, which 
suggested that IM might be the causative agent.40 The authors 
suggested that non-deiodination clearance was the most likely 
mechanism responsible for IM-induced hypothyroidism in 
patients who receive replacement therapy.
At present it appears reasonable to monitor TSH levels 
more frequently in IM-treated patients on thyroid replace-
ment. Moreover, based on the findings of overt hypothy-
roidism secondary to the use of other TKIs, it would also be 
prudent to monitor thyroid function in patients who exhibit 
symptoms of hypothyroidism.
Immune function
In view of the several off-target kinases that IM and other 
TKIs inhibit, such as c-kit and PDGF-R, which play a nor-
mal physiological role in immune responses, it has been 
  speculated that these drugs will probably have an impact on 
the immune responses of patients. Recently, investigators have 
reported a range of effects, from   hypogammaglobulinemia 
Table 2 imatinib and reproduction: suggested recommendations 
to providers for patients taking imatinib by gender
Female Male
Pregnancy category D Spermatogenesis in male 
patients taking imatinib 
has not been thoroughly 
evaluated
Discuss risks and benefits of 
imatinib to fetus if patient 
becomes pregnant
Could lead to oligospermia
Consider alternative agents 
or observation if female 
patient becomes pregnant
Small risk of gynecomastia
Do not breast feed while 
taking imatinibBiologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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to a suppressive effect on T- and NK-cell activation and 
cytotoxicity in vitro.41 While hypogammaglobulinemia is 
typically associated with chronic lymphocytic leukemia, it 
is uncommon in untreated CML. Santachiara et al reported 
significant hypogammaglobulinemia in about 10% of an 
87-patient study group treated with IM for CML or GIST.42 
It is also of interest that ad hoc reports suggest the presence 
of uncommon opportunistic infections, including peritoneal 
tuberculosis and atypical candida pneumonia, in patients 
on IM who were not neutropenic or had clinical signs of 
immunosuppression.43
There are also reports supporting the notion that the 
immune effects mediated by IM might be global, with impair-
ment of the function of human regulatory T cells (Tregs) and 
antigen presenting cells.44 IM has also been speculated to 
reverse the inhibition of immune responses to IM-resistant 
CML cells by Tregs.
Cutaneous toxicity
Cutaneous reactions are probably TKI-class related and often 
seen in patients with CML on IM. The precise incidence of 
rashes appears to be around 35%, with most associated with 
pruritus.45 It is not entirely clear if these are dose related or 
not; the prevalence appears to be maximum in the early stages 
of IM treatment. Severe life-threatening exfoliative dermatitis 
and Stevens–Johnsons syndrome have also been reported on 
rare occasions and have generally occurred within 10 days 
of starting therapy.46 In most, if not all, cases the rash and 
pruritus subside significantly with treatment interruption 
alone; on some occasions, the addition of a short course of 
steroids is helpful.47–49
Though long-term rashes are less common, it is not 
uncommon to witness intermittent reappearance of rash 
and pruritus, particularly if the dose of IM is escalated.50,51 
Other forms of cutaneous toxicity associated with IM 
is skin hyper/hypopigmentation, which appears to per-
sist even when IM is discontinued. Hypopigmentation, 
perhaps related to inhibition of c-kit, may or may not be 
associated with rash and is more prevalent in ethnically 
pigmented patients.52–54 It is of considerable interest 
that IM has also been associated with repigmentation of 
gray hair. In a study of 133 patients with CML on IM, 8 
patients noted progressive repigmentation of scalp gray 
hair.55 Whereas hyperpigmentation of skin and hair is 
more commonly seen in patients with fair complexions, 
other toxicities, such as dry skin, pruritus, and photosen-
sitivity present in all patients, often early, and may persist 
throughout therapy.56
Hepatotoxicity
About 5% of all patients with CML appear to develop mild 
(grade 1/2) hepatotoxicity characterized by an abnormal 
bilirubin and transaminases within the first 2 years of 
receiving IM. Serious hepatotoxicity (grade 3/4) is, however, 
extremely rare.4 In all cases, the hepatic dysfunction appears 
to be fully reversible with dose interruption/dose   reduction. 
Talpaz et al reported a patient on IM who developed severe 
hepatic failure and died while receiving concurrent acetamin-
ophen.58 Other case reports of fatal hepatic failure related to 
IM pertain to a patient with myelofibrosis/polycythemia vera 
who received IM at 400 mg/day, and a patient who had a liver 
transplant for the treatment of suspected imatinib-induced 
acute liver failure.57,58
It is, therefore, prudent to monitor hepatic function 
frequently, perhaps once weekly to commence and thereaf-
ter about once a month. In patients who experience grade 
3–4 hepatotoxicity, it is appropriate to discontinue IM and 
reintroduce treatment cautiously once the liver chemistry 
has normalized. Some specialists advocate the use of ste-
roids, and indeed reports of a regression of hepatotoxicity 
and allowing imatinib therapy to be continued have been 
documented.59,60
Pulmonary toxicity
Pulmonary toxicity causally related to IM therapy is 
uncommon. Ohnishi et al collated data from 27 patients 
who appeared to have developed interstitial lung disease 
(ILD) while on IM therapy.61 The majority of these patients 
(23 of 27) either improved or had complete resolution of 
ILD with the discontinuation of IM and the addition of low 
doses of short-term steroids. Due to the very rare occurrence 
of this side effect, there is no firm consensus with regard to 
its optimal management. It is probably reasonable to with-
hold IM therapy until the pulmonary functions recover and 
consider alternative therapy thereafter.
Secondary malignancies
There has been considerable interest with regard to the poten-
tial for TKIs to result in secondary malignancies,   particularly 
in regards to myeloid malignancies. This stemmed largely 
from observations made in a small cohort of patients with 
CML receiving IM who developed diverse chromosomal 
abnormalities in the Ph-negative metaphases as they achieved 
major or CCyR.62–66 Initially, it was speculated that these 
findings were transient and probably not sinister, but of 
unknown clinical consequences. Thereafter, multiple reports 
appeared pertaining to patients with CML with chromosomal Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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Table 3 incidence of notable short- and long-term reported toxicities of imatinib
Percentage .10% 1% –10% ,1.0%
Short-term toxicities Superficial edema, muscle cramps, 
nausea, musculoskeletal pain, 
diarrhea, rash, fatigue, headache, 
abdominal pain, joint pain
Pancytopenia, febrile 
neutropenia, flushing, 
liver function test 
abnormalities
Pleural effusion, syncope, angioedema
Long-term toxicities 
 
 
 
 
NA 
 
 
 
 
NA 
 
 
 
 
Cardiac toxicities, secondary malignancy, myositis, 
multiple sclerosis, renal failure, dermatitis 
pancreatitis, hypophosphatemia, gynecomastia, 
hypogammaglobulinemia, opportunistic infections, 
hepatotoxicities, pulmonary toxicities, skin 
hyper/hypopigmentation, cerebral edema
Abbreviation: NA, not applicable.
abnormalities in the Ph-negative metaphases treated with 
IM alone or in combination with other agents who go on 
to develop myelodysplastic syndrome/acute myelogenous 
leukemia (MDS/AML). Kovitz et al analyzed 1,701 patients 
and reported 3 patients treated with IM for CML who subse-
quently developed AML (n = 1) and high-risk MDS (n = 2).67 
In a further series from the MD Anderson Hospital in Texas 
involving 258 patients with newly diagnosed CML treated 
with first-line IM, at median follow-up of 37 months, chro-
mosomal abnormalities in Ph-negative metaphases occurred 
in 9% of patients.68 These investigators also noted a patient 
with monosomy 7, who developed AML, but no evidence of 
dysplasia or acute leukemia was seen in any other patients.
It has been hypothesized that these effects were probably not 
solely secondary to IM since these changes have not been reported 
in diseases other than CML treated with IM, and they occur in 
patient with CML treated with alternative drugs, including inter-
feron. Regardless, it is useful to monitor patients on IM with bone 
marrow aspirations and cytogenetic analysis if a secondary clonal 
event is suspected. The emergence of Ph-negative metaphase 
chromosomal abnormalities in this scenario is not necessarily an 
absolute indication to change the treatment strategy per se unless 
additional complications (trilineage dysplasia) arise.
With regard to nonmyeloid malignancies, there was much 
speculation of the possible increase in the risk of urothelial 
malignancies in a small cohort of patients subjected to 
  imatinib.61 Importantly, however, a much larger study of 9,000 
patients failed to confirm this suspicion.62
Conclusion
Long-term side effects of IM are now being well documented 
and appear rare. Table 3 shows the incidence of long-term 
adverse effects compared with the acute adverse effects. It is 
likely that as ongoing follow-up of earlier studies that have 
basically evolved into longitudinal studies continues, additional 
long-term complications and increased incidence of current 
known complications may be noted. It is recommended that 
specialists remain cautious about the potential long-term 
adverse effects associated with IM. Some specialists have 
observed rare but potential sinister effects: Ebnöether et al noted 
the potentially lethal toxicity of cerebellar edema in 2 sepa-
rate patients, but this has not been noted in other cases in the 
  literature or in extended follow-up.69 In addition, other possibly 
significant long-term complications noted from case reports and 
small retrospective reviews, including optic effects and sen-
sorineural hearing loss, have been noted but are not prominent 
in any of the larger studies or retrospective reviews.
The above findings highlight some of the issues evaluating 
the long-term toxicities of a drug that is in its relative infancy. 
Some findings that may be present in the preclinical setting 
are not always evident in the clinical setting, and vice versa. 
While case reports and retrospective reviews are an integral 
part of clinical practice, there can be many confounding 
variables that lead to adverse toxicities that in fact may not 
be secondary to the suspected offending agent. Importantly, 
it would appear that following a decade since IM entered 
the clinics, the safety analysis suggests that the long-term 
adverse effects are quite acceptable.
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